PMID- 36033564
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220830
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2022
DP  - 2022
TI  - Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced 
      Esophageal Cancer: A Single-Center Retrospective Observational Study.
PG  - 7331687
LID - 10.1155/2022/7331687 [doi]
LID - 7331687
AB  - This study is aimed at assessing the sintilimab-based regimens' safety and 
      efficacy for advanced esophageal cancer (EC) treatment in the real world. Cases 
      of advanced EC treated with sintilimab-based regimens in the Anyang Tumor 
      Hospital between 1 January 2020 and 1 August 2021 were retrospectively examined. 
      Progression-free survival (PFS), overall survival (OS), disease control rate 
      (DCR), objective response rate (ORR), and adverse events (AEs) were evaluated. 
      Among the 50 included patients, the median PFS was 11.3 months (95% CI: 5.0-17.6 
      months), and the 1-year PFS rate was 49.2%. The median OS was not reached, and 
      the 1-year OS rate was 67.1%. Complete response (CR), partial response (PR), 
      stable disease (SD), and progressive disease (PD) were seen in 14% (n = 7), 46% 
      (n = 23), 32% (n = 16), and 8% (n = 4) of the 50 patients, respectively. 
      Therefore, the ORR and DCR were 60% (30/50) and 92% (46/50), respectively. The CR 
      rate of patients with radiotherapy was higher than that without radiotherapy (25% 
      vs. 3.8%, P = 0.031). The 1-year OS rate was higher in patients with radiotherapy 
      than in patients without radiotherapy (85.9% vs. 53.2%, P = 0.020). The most 
      observed AEs included anemia, decrease in white blood cell count, 
      nausea/vomiting, and hypoproteinemia. Sintilimab-based regimens achieved good 
      disease control and tolerance for treating advanced EC in the real world. 
      Combined radiotherapy can improve the efficacy and deserves further study.
CI  - Copyright (c) 2022 Chenyu Wang et al.
FAU - Wang, Chenyu
AU  - Wang C
AUID- ORCID: 0000-0002-9993-6663
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Jin, Linzhi
AU  - Jin L
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Cheng, Xinyu
AU  - Cheng X
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Ren, Runchuan
AU  - Ren R
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Zheng, Anping
AU  - Zheng A
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Hao, Anlin
AU  - Hao A
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Wang, Nengchao
AU  - Wang N
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Zhang, Jinwen
AU  - Zhang J
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Zhou, Fuyou
AU  - Zhou F
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
FAU - Zhang, Yaowen
AU  - Zhang Y
AUID- ORCID: 0000-0002-2141-1429
AD  - Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor 
      Hospital of Henan University of Science and Technology, Henan Medical Key 
      Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 
      455000, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220805
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 8FU7FQ8UPK (sintilimab)
SB  - IM
MH  - *Antibodies, Monoclonal, Humanized
MH  - *Esophageal Neoplasms
MH  - Humans
MH  - Progression-Free Survival
MH  - Retrospective Studies
PMC - PMC9410816
COIS- The authors declare that they have no conflict interests.
EDAT- 2022/08/30 06:00
MHDA- 2022/08/31 06:00
PMCR- 2022/08/05
CRDT- 2022/08/29 04:56
PHST- 2022/06/06 00:00 [received]
PHST- 2022/07/19 00:00 [accepted]
PHST- 2022/08/29 04:56 [entrez]
PHST- 2022/08/30 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/08/05 00:00 [pmc-release]
AID - 10.1155/2022/7331687 [doi]
PST - epublish
SO  - Biomed Res Int. 2022 Aug 5;2022:7331687. doi: 10.1155/2022/7331687. eCollection 
      2022.